News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

PledPharma establishes a Scientific Advisory Board for the continued clinical development of PledOx®

August 24, 2017

PledPharma AB
Company Announcement

PledPharma establishes a Scientific Advisory Board for the continued clinical
development of PledOx®

Stockholm, 2017-08-24 08:00 CEST (GLOBE NEWSWIRE) -- 
PledPharma announces today that a number of internationally leading experts
will join in a newly established Scientific Advisory Board to support the
company during the continued clinical development of PledOx®. 

The aim of the Scientific Advisory Board (SAB) is to give PledPharma valuable
advice on the design of the remaining clinical trial program and the regulatory
strategy for PledOx®, with the goal of maximizing the likelihood for regulatory
approval and optimizing the drug candidate's commercial potential. In a Phase
IIb study PledOx® has shown to prevent symptoms of serious nerve damage in
patients undergoing chemotherapy treatment. 

The SAB will consist of the following internationally leading experts in
oncology, neurology, chronic pain management and methods for measuring
patients' reported outcome. 

Professor Guido Cavaletti, MD, PhD and Head of the Neuroimmunology Center at S.
Gerardo Hospital and the Experimental Neurology Unit at the School of Medicine,
University of Milan-Biocca in Monza, Italy and international expert in
chemotherapy induced peripheral neuropathy. 

Professor David Cella, PhD, Chair of the Department of Medical Social Sciences
at Northwestern University Feinberg School of Medicine in Chicago, USA. Expert
in evaluations of patient-reported outcomes in clinical trials. 

Professor emeritus Bengt Glimelius, MD, PhD. Professor emeritus in oncology at
the University of Uppsala and Consultant at the University hospital.
Coordinating principal investigator in the PLIANT trial - PledPharma's Phase
IIb Study with PledOx®. 

Associate professor Rolf Karlsten, MD, PhD. Specialist in anesthesiology,
intensive care and neuropathic pain management. Head of Rehabilitation Medicine
and Pain Center at Uppsala Academic Hospital. 

The SAB also includes a non-disclosed American who is a leading international
expert in chemotherapy induced peripheral neuropathy. 

"The significant need for a drug that can prevent chemotherapy induced nerve
damage and the unique clinical results that PledOx® demonstrated in the
completed Phase IIb study has made it possible to attract these distinguished
international experts within the fields of oncology, neurology and Patient
Reported Outcome to PledPharma's Scientific Advisory Board. I look forward to
their support in our continued efforts to take PledOx® further towards a market
registration, "says PledPharma’s CEO Nicklas Westerholm. 

Detailed descriptions of the members of the SAB are available on the company's

For more information, please contact:

Nicklas Westerholm, CEO, phone: +46 73 354 20 62

Michaela Gertz, CFO, phone: +46 709 26 17 75

About PledPharma

PledPharma develops new drugs that protect the body against oxidative stress –
a potentially debilitating and sometimes life-threatening condition that can be
caused by chemotherapy treatment and following acetaminophen (paracetamol)
overdose. The company's most advanced project PledOx® is being developed to
reduce nerve damage associated with chemotherapy. A phase IIb study has been
conducted and will serve as the basis for the continued development. The drug
candidate Aladote® is being developed to reduce the risk of acute liver failure
associated with acetaminophen poisoning. PledPharma (STO: PLED) is listed on
Nasdaq First North. Erik Penser Bank is the company’s Certified Adviser (tel
+46 8 463 80 00). For more information, see



Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10